A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial ID #	NCT02853318
Phase	II
Drug Class	Angiogenesis Inhibitors: VEGF
Drug Name	Bevacizumab
Alternate Drug Names	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial	Bevacizumab, Cyclophosphamide, Pembrolizumab
Eligible Participant	Platinum resistant or refractory ovarian cancer
Patients Enrolled	30, mean of 3.8 prior therapies
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	CBR, ORR, DCR, PFS, evaluated per irRECIST
Efficacy	pembrolizumab 200 mg in combination with bevacizumab 15 mg/kg every 3 weeks and oral cyclophosphamide 50 mg every day ORR: 43.3% (3CR, 10PR, n=30) DCR: 93.3% (3CR, 10PR, 15SD, n=30) CBR: 70% (3CR, 10PR, 8SD, n=30) PFS: 7.6 months
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE: hypertension (15%)
Conclusion	Bevacizumab+pembrolizumab+cyclophosphamide is well tolerated and demonstrates clinical benefit and durable treatment responses
Reference	Zsiros E et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol (2020) 7(1):78-85 https://pubmed.ncbi.nlm.nih.gov/33211063/